Polysulfated glycosaminoglycan (PSGAG), sold under the brand name Adequan, is an injectable drug for dogs (Adequan® Canine) and horses (Adequan® I.M) that is used to alleviate the lameness, pain, and lowered range of motion caused by arthritis.
Adequan® Canine (polysulfated glycosaminoglycan) is the only FDA-approved disease-modifying osteoarthritis drug (DMOAD) that inhibits cartilage loss in the dog’s joints, and may help to:
Restore joint lubrication
Renew the building blocks of healthy cartilage
Adequan® I.M for Horses
As the only FDA-approved equine PSGAG (polysulfated glycosaminoglycan) for degenerative joint disease (DJD) in horses, Adequan® i.m. actually treats degenerative joint disease (DJD), not just its clinical signs. It contributes to:
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.